(Q40354471)

English

Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model

scientific article published on 4 November 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

adaptive radiation therapy

0 references

cervix uterine cancer

1 reference

based on heuristic

inferred from title

William E Grizzle

6

object named as

William E Grizzle

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

J Michael Straughn

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Patsy G Oliver

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Tong Zhou

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Wenquan Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Ronald D Alvarez

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Donald J Buchsbaum

7

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

0 references

publication date

4 November 2005

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

101

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

46-54

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

The epidemiology of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

A novel receptor for Apo2L/TRAIL contains a truncated death domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

The receptor for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

On testing for drug/chemical interactions: definitions and inference

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group stud

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Death receptors in chemotherapy and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.053

7 January 2021

Identifiers

10.1016/J.YGYNO.2005.09.053

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40354471&oldid=2043342649"